NSNicholas Gerard Smedira

Nicholas Gerard Smedira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicholas Gerard Smedira has a total of 185 co-authors. Here are the top co-authors by number of shared publications:

  • Milind Y. Desai

    Heart, Vascular and Thoracic Institute, Cleveland Clinic , 9500 Euclid Avenue, Desk J1-5, Cleveland, OH 44195

    10 shared publications
  • Eugene H. Blackstone

    Department of Thoracic & Cardiovascular Surgery, Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH

    9 shared publications
  • Bo Xu

    Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA

    4 shared publications
  • Maran Thamilarasan

    Hypertrophic Cardiomyopathy Center, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk J1-5, Cleveland Clinic , Cleveland, OH 44195, USA

    4 shared publications
  • Zoran B. Popovic

    Heart, Vascular and Thoracic Institute, Cleveland Clinic , 9500 Euclid Avenue, Desk J1-5, Cleveland, OH 44195

    4 shared publications
  • Amy J. Sehnert

    Bristol Myers Squibb Princeton New Jersey USA

    3 shared publications

Latest Publications

  • Incremental prognostic value of late gadolinium enhancement in hypertrophic cardiomyopathy in a large contemporary cohort

    by Susan K Keen, Stuti Shah, Hesham Sheashaa, Mohammed Abusafia, Shada Jadam, Simrat Kaur, Andrew Gaballa, Susan Ospina, Katy Rutkowski, Jay Ramchand, et al.

    Aims: Extensive late gadolinium enhancement (LGE) is recognized in contemporary hypertrophic cardiomyopathy (HCM) risk assessment, but the prognostic value of lower quantitative thresholds remains debated. We aimed to evaluate whether quantitative LGE provides independent and incremental prognostic information beyond established clinical and phenotypic risk markers. Methods and results: This large contemporary cohort included 3035 patients (median age 58 years, 57% men); 56% had LGE, including 242 (8%) with LGE > 10%. Most patients have obstructive hypertrophic cardiomyopathy (71%), 1498 (69%) of which subsequently underwent septal reduction therapy at a median of 43 days [interquartile range (IQR) 5–107) from the cardiac magnetic resonance (CMR) date (1485 myectomies and 13 alcohol septal ablations). Over a median of 8.8 years, 331 (11%) primary endpoints occurred [295 cardiovascular deaths (9.7%) and 36 appropriate implantable cardioverter–defibrillator discharges (1.3%)]. On multivariable Cox proportional hazards analysis [adjusted for standard clinical and CMR variables, higher %LGE (1.05 per 1% increase, 95% confidence interval 1.03–1.06; P < 0.001)] was associated with primary events. Compared with no LGE, LGE ≥10% was associated with higher risk of the composite endpoint. Conclusion: In this large contemporary HCM cohort, quantitative LGE was independently associated with long-term adverse outcomes. LGE ≥10% identified patients at significantly higher risk, and incorporation of LGE improved discrimination beyond ESC and AHA/ACC risk assessment.

  • Open Access

    A surgeon's toolkit for mitral valve–induced left ventricular outflow tract obstruction with minimal septal hypertrophy

    by Jean-Luc A. Maigrot, David Moros, Eugene H. Blackstone, Aaron J. Weiss, Milind Y. Desai, A. Marc Gillinov, Nicholas G. Smedira


  • Top Cited Papers
    Open Access

    Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM

    by Milind Y. Desai, Kathy Wolski, Anjali Owens, Jeffrey B. Geske, Sara Saberi, Andrew Wang, Mark Sherrid, Paul C. Cremer, Neal K. Lakdawala, Albree Tower-Rader, et al.

    BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov ; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128. METHODS: A double-blind randomized placebo-controlled multicenter trial at 19 sites in the United States included symptomatic obstructive HCM patients referred for SRT (enrollment July 2020 through October 2021). The group initially randomized to mavacamten continued the drug for 128 weeks and the placebo to mavacamten group from week 16 to 128 (112-week exposure). Dose titrations were performed using echocardiographic left ventricular outflow tract gradient and left ventricular ejection fraction measurements. The principal end point was proportion of patients proceeding with SRT or remaining guideline-eligible at week 128. RESULTS: At week 128, 17 of 108 (15.7%) patients in the total study sample met the composite end point (7 underwent SRT, 1 was SRT-eligible, and 9 SRT-status unevaluable). Additionally, 87 of 108 (80.5%) patients demonstrated ≥1 New York Heart Association class improvement by week 128, and 52 of 108 (48.1%) demonstrated ≥2, with a sustained reduction in resting and Valsalva left ventricular outflow tract gradients of 38.2 mm Hg and 59.4 mm Hg, respectively. Ninety-five of 108 (88%) patients transitioned to commercial mavacamten. Overall, 15 of 108 (13.8%) patients (5.41 per 100 patient-years) had an left ventricular ejection fraction <50% (2 with left ventricular ejection fraction ≤30%; 1 death). Of these, 12 of 15 (80%) continued treatment. New-onset atrial fibrillation occurred in 11 (10.2%) patients (4.55 per 100 patient-years). CONCLUSIONS: In severely symptomatic obstructive HCM patients, sustained freedom from SRT was observed at 128 weeks, with nearly 90% patients remaining on long-term mavacamten. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.


  • Open Access

    Echocardiographic Changes Following Surgical Myectomy in Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the SPIRIT‐HCM Study

    by Milind Y. Desai, Natalie Szpakowski, Albree Tower‐Rader, Barb Bittel, Agostina Fava, Susan Ospina, Bo Xu, Maran Thamilarasan, Amgad Mentias, Nicholas G. Smedira, et al.

    Background: In obstructive hypertrophic cardiomyopathy, myectomy improves symptoms, quality of life, and left ventricular (LV) outflow tract gradients. We prospectively evaluated the temporal changes in various echo parameters after myectomy. Methods and Results: In 173 adults with obstructive hypertrophic cardiomyopathy (53±10 years, 63% men) who underwent myectomy between March 2017 and June 2020, clinical and blinded echo assessment (before and at 12±6 months follow‐up) was performed prospectively (SPIRIT‐HCM [Quality of Life and Functional Capacity Following Septal Myectomy in Obstructive Patients With Hypertrophic Cardiomyopathy]). Changes in echocardiographic parameters (left atrial volume index, E / e ′, LV outflow tract gradients, along with average LV global longitudinal strain on apical 2‐, 3‐, and 4‐chamber views and regional LV strain from apical 4‐chamber view) were measured in 126 patients. There was significant improvement in left atrial volume index (−6.9 mL/m 2 [95% CI, 4–9.7]), E / e ′ (−2.9 [95% CI, −2.7 to −4.1]) and peak LV outflow tract gradient (−94 mm Hg [95% CI −87 to −100]) from baseline to follow‐up (both P P =0.09) and midseptal (−0.98% [95% CI, −1.93 to 0.02], P =0.05) LV strain, worsening in apical septal strain (−4.5% [95% CI, −5.9 to −3.0], P P P =0.30). There was no correlation between change in LV‐global longitudinal strain and change in 6‐minute walk time (r=0.12, P =0.24) or Kansas City Cardiomyopathy Questionnaire summary score change (r=0.02, P =0.85), whereas it was significantly associated with change in E / e ′ (r=0.29, P =0.003). Conclusions: In patients with obstructive hypertrophic cardiomyopathy, myectomy improved various echocardiography parameters at 1‐year; however, LV‐global longitudinal strain remained unchanged. Registration: URL: https://clinicaltrials.gov ; Unique identifier: NCT03092843.


  • Open Access

    Contemporary Clinical Characteristics, Imaging, Management, and Surgical and Nonsurgical Outcomes of Adult Patients With Subaortic Stenosis

    by Ankit Agrawal, Aro Daniela Arockiam, Muhammad Majid, Ushasi Saraswati, Joseph El Dahdah, Sanya Chandna, Joseph Kassab, Michel Chedid El Helou, Rishabh Khurana, Tiffany Dong, et al.

    Background: Subaortic stenosis (SAS) is characterized by a fibromuscular membrane located just below the aortic valve, causing fixed outflow tract obstruction. There is a paucity of studies evaluating this condition. This cohort study reviewed the contemporary characteristics and outcomes of SAS in adult patients in a single large referral center. Methods and Results: We retrospectively studied adult patients with SAS evaluated at our center during 2011 to 2022. The primary outcome was all‐cause mortality and heart failure hospitalizations during follow‐up, with secondary end points including recurrence of SAS and repeat surgery after initial SAS surgery. Among 484 patients with SAS, key characteristics included mean age 55±18 years, 67.5% female, left ventricular outflow tract peak velocity 352±140 cm/s and gradient 57±40 mm Hg, left ventricular ejection fraction 60%±14%, 54.8% had prior SAS surgery, and 45.1% had surgery during follow‐up. Over a median follow‐up of 5.5 (1.5–12.3) years, 11.5% (n=56) died, 6.8% (n=33) had heart failure hospitalizations, 8.0% (n=39) experienced SAS recurrence, and 14 (5.9%) underwent repeat SAS surgery. Multivariable analyses identified older age per 10‐years (hazard ratio [HR], 1.37 [95% CI, 1.12–1.68]) and baseline New York Heart Association class (HR, 2.48 [95% CI, 1.54–3.99]) to be statistically significantly associated with the primary end point; higher body mass index, New York Heart Association class, and peak left ventricular outflow tract gradient were also statistically significantly associated with SAS recurrence and redo surgery. Conclusions: Almost half of patients with SAS had surgery in the past or during follow‐up, and a significant minority had mortality or morbidity events during follow‐up. Identified prognosticators warrant further research to guide management.


  • Open Access

    Radical Pericardiectomy and Use of Cardiopulmonary Bypass for Constrictive Pericarditis

    by Marijan Koprivanac, Karolis Bauza, Nicholas Smedira, Gosta B. Pettersson, Shinya Unai, Paola Barrios, Nicholas Oh, Filip Stembal, Valentina Lara-Erazo, Edward G. Soltesz, et al.

    Background: Pericardiectomy is definitive treatment for constrictive pericarditis. However, extent of resection (radical versus partial) and use of cardiopulmonary bypass (CPB) are debated. Objectives: To determine the association of extent of pericardial resection and use of CPB with outcomes. Methods: From January 2000 to January 2022, 565 patients with constrictive pericarditis underwent radical (n=445, 314 [71%] on CPB) or partial (n=120, 67 [56%] on CPB) pericardiectomy at Cleveland Clinic. Outcomes stratified by extent of pericardial resection and use of CPB were compared after propensity-score matching. Results: Both radical pericardiectomy and CPB use (67% [381/565]) increased over time. Among 88 propensity-matched pairs (73% of possible matches), immediate postoperative cardiac index increased ( P P =.50). Median postoperative hospital length of stay was 10 versus 8.5 days ( P =.02). Operative mortality was 9.1% (8/88) versus 6.8% (6/88) ( P =.58). 10-year survival was 54% versus 41%, with a higher propensity-adjusted hazard ratio after partial resection (1.9, 95% CI 1.2-3.1). Conclusions: When surgical intervention is deemed necessary, radical — rather than partial — resection for constrictive pericarditis can be performed with low surgical mortality and morbidity. Radical pericardiectomy can be accomplished on CPB and results in better long-term survival. CLINICAL PERSPECTIVES: Patients with constrictive pericarditis require a multidisciplinary approach involving primarily a cardiologist and cardiac surgeon, and other disciplines like gastroenterology since liver cirrhosis from increased central venous pressure and congestion is common, or immunology for evaluation of possible autoimmune etiology. Communication is critical in managing patient expectations after pericardiectomy, especially linking etiology to short- and long-term outcomes in this complex patient population. Radical pericardiectomy should be the gold standard for treating patients with constrictive pericarditis. Routine use of cardiopulmonary bypass is safe and enables the radical pericardiectomy surgery and should be recommended in the guidelines.